Ukr.Biochem.J. 2026; Volume 98, Issue 2, Mar-Apr, pp. 69-75

Plasma level of von Willebrand factor in patients in the early stages of recovery after atherothrombotic stroke

13.04.2026   Uncategorized

O. Ya. Mykhalojko, V. A. Hryb, I. Ya. Mykhalojko

Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine.
*e-mail: myhalojko@i.ua

Received: 21 November 2025; Revised: 23 February 2026;
Accepted: 03 April 2026; Available on-line: April 2026

Atherothrombotic ischemic stroke remains a leading cause of disability and mortality. The search for biomarkers of its recurrence is a key task of modern vascular neurology. Von Willebrand factor (vWF), a multimeric glycoprotein that binds platelets to damaged vessel, is considered a marker of endothelial dysfunction and platelet activity. The aim of the study was to assess the level of von Willebrand factor in the blood plasma of patients in the early stages of recovery after atherothrombotic stroke. 200 patients aged 60.42 ± 7.40 with atherothrombotic ischemic stroke and 50 people from the control group were examined. The prospective observation was conducted for 12 months to record recurrent strokes. Neurological deficit was assessed using the National Institutes of Health Stroke Scale and results were interpreted according to the generally accepted stroke grading. The level of vWF was determined by the light-transmission analysis on a laser aggregometer. The data obtained showed that the level of vWF in the early recovery period increased in parallel with the increase in disorder severity to 137.7, 155.7 and 169.7% in the groups with easy, average, and severe stroke, respectively, compared with the control indicator of 95.3%. In patients with the highest vWF level (>170%), the recurrent ischemic strokes were recorded in half of the cases. These results indicate the сlinical significance and prognostic value of von Willebrand factor, in particular, for identifying the patients at high risk of recurrent vascular accidents requiring enhanced secondary prevention measures.

Keywords: , , , ,

References:

  1. Barakzie A, Jansen AJG, Ten Cate H, de Maat MPM. Coagulation biomarkers for ischemic stroke. Res Pract Thromb Haemost. 2023;7(4):100160. PubMed, PubMedCentral, CrossRef
  2. Mereuta OM, Abbasi M, Arturo Larco JL, Dai D, Liu Y, Arul S, Kadirvel R, Hanel RA, Yoo AJ, Almekhlafi MA, Layton KF, Delgado Almandoz JE, Kvamme P, Mendes Pereira V, Jahromi BS, Nogueira RG, Gounis MJ, Patel B, Aghaebrahim A, Sauvageau E, Bhuva P, Soomro J, Demchuk AM, Thacker IC, Kayan Y, Copelan A, Nazari P, Cantrell DR, Haussen DC, Al-Bayati AR, Mohammaden M, Pisani L, Rodrigues GM, Puri AS, Entwistle J, Meves A, Savastano L, Cloft HJ, Nimjee SM, McBane RD 2nd, Kallmes DF, Brinjikji W. Correlation of von Willebrand factor and platelets with acute ischemic stroke etiology and revascularization outcome: an immunohistochemical study. J Neurointerv Surg. 2023;15(5):488-494. PubMed, CrossRef
  3. Mykhaloiko OJ, Gryb VA, Fabryka IM, Hotsaniuk OI, Shalamai UP, Salyzhyn TI, Mykhaloiko IJ. Diagnostic value of lipoprotein-associated phospholipase A2 in patients in the early recovery period of atherothrombotic stroke. Wiad Lek. 2025;78(6):1119-1124. PubMed, CrossRef
  4. Mykhaloiko OJ, Hrytsiuk TD, M Fabryka IR, Hotsaniuk OI, Kulaiets VM, Mykhaloiko IJ. Ultrasonographic changes of carotid vessels in patients in the early recovery period of atherothrombotic stroke. Wiad Lek. 2024;77(7):1372-1376. PubMed, CrossRef
  5. Geppert A, Zorn G, Delle-Karth G, Koreny M, Siostrzonek P, Heinz G, Huber K. Plasma concentrations of von Willebrand factor and intracellular adhesion molecule-1 for prediction of outcome after successful cardiopulmonary resuscitation. Crit Care Med. 2003;31(3):805-811. PubMed, CrossRef
  6. Fogarty H, Doherty D, O’Donnell JS. New developments in von Willebrand disease. Br J Haematol. 2020;191(3):329-339. PubMed, PubMedCentral, CrossRef
  7. Taylor A, Vendramin C, Singh D, Brown MM, Scully M. von Willebrand factor/ADAMTS13 ratio at presentation of acute ischemic brain injury is predictive of outcome. Blood Adv. 2020;4(2):398-407. PubMed, PubMedCentral, CrossRef
  8. Okubo N, Sugawara S, Fujiwara T, Sakatsume K, Doman T, Yamashita M, Goto K, Tateishi M, Suzuki M, Shirakawa R, Eura Y, Kokame K, Hayakawa M et al. von Willebrand factor Ristocetin co-factor activity to von Willebrand factor antigen level ratio for diagnosis of acquired von Willebrand syndrome caused by aortic stenosis. Res Pract Thromb Haemost. 2023;8(1):102284. PubMed, PubMedCentral, CrossRef
  9. Yan B, Wang Q, Du W, Zhai S, Gou C, Hu T, Xia L, Ruan C, Zhao Y. Elevated Plasma von Willebrand Factor Antigen and Activity Levels Are Associated With the Severity of Coronary Stenosis. Clin Appl Thromb Hemost. 2020;26:1076029619900552. PubMed, PubMedCentral, CrossRef
  10. Wannamethee SG, Papacosta O, Lennon L, Whincup PH. Serum magnesium and risk of incident heart failure in older men: The British Regional Heart Study. Eur J Epidemiol. 2018;33(9):873-882. PubMed, PubMedCentral, CrossRef
  11. Favaloro EJ, Bonar R, Hollestelle MJ, Jennings I, Mohammed S, Meijer P, Woods T, Meiring M. Differential sensitivity of von Willebrand factor activity assays to reduced VWF molecular weight forms: A large international cross-laboratory study. Thromb Res. 2018;166:96-105. PubMed, CrossRef
  12. Ng CJ, Di Paola J. von Willebrand Disease: Diagnostic Strategies and Treatment Options. Pediatr Clin North Am. 2018;65(3):527-541. PubMed, CrossRef
  13. Wu N, Chen Y, Hou M. Level of von Willebrand factor to assess the occurrence and prognosis of acute myocardial infarction. Ann Palliat Med. 2021;10(10):10444-10449. PubMed, CrossRef
  14. Nowakowski T, Malinowski KP, Niżankowski R, Iwaniec T, Undas A. Restenosis is associated with prothrombotic plasma fibrin clot characteristics in endovascularly treated patients with critical limb ischemia. J Thromb Thrombolysis. 2019;47(4):540-549. PubMed, PubMedCentral, CrossRef
  15. Kamatani K, Kenzaka T, Sugimoto R, Kumabe A, Kitao A, Akita H. Multiple thrombosis associated with Cytomegalovirus enterocolitis in an immunocompetent patient: a case report. BMC Infect Dis. 2021;21(1):530. PubMed, PubMedCentral, CrossRef
  16. Larkin D, de Laat B, Jenkins PV, Bunn J, Craig AG, Terraube V, Preston RJ, Donkor C, Grau GE, van Mourik JA, O’Donnell JS. Severe Plasmodium falciparum malaria is associated with circulating ultra-large von Willebrand multimers and ADAMTS13 inhibition. PLoS Pathog. 2009;5(3):e1000349. PubMed, PubMedCentral, CrossRef
  17. Bongers TN, de Maat MP, van Goor ML, Bhagwanbali V, van Vliet HH, Gómez García EB, Dippel DW, Leebeek FW High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. Stroke. 2006;37(11):2672-2677. PubMed, CrossRef
  18. Williams SR, Hsu FC, Keene KL, Chen WM, Dzhivhuho G, Rowles JL 3rd, Southerland AM, Furie KL, Rich SS, Worrall BB, Sale MM. Genetic Drivers of von Willebrand Factor Levels in an Ischemic Stroke Population and Association With Risk for Recurrent Stroke. Stroke. 2017;48(6):1444-1450. PubMed, PubMedCentral, CrossRef
  19. Ruggeri ZM. The role of von Willebrand factor in thrombus formation. Thromb Res. 2007;120(Suppl 1):S5-S9. PubMed, PubMedCentral, CrossRef
  20. Hamilos M, Petousis S, Parthenakis F. Interaction between platelets and endothelium: from pathophysiology to new therapeutic options. Cardiovasc Diagn Ther. 2018;8(5):568-580. PubMed, PubMedCentral, CrossRef
  21. Sadler JE. von Willebrand factor: two sides of a coin. J Thromb Haemost. 2005;3(8):1702-1709.
    PubMed, CrossRef
  22. Vischer UM. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost. 2006;4(6):1186-1193. PubMed, CrossRef
  23. Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357(24):2482-2494. PubMed, CrossRef
Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.